Real-world comparative outcomes of darolutamide- versus abiraterone-based triplet therapy for metastatic hormone-sensitive prostate cancer: a retrospective cohort study
Therapeutic Advances in Urology · 2026-07 · 18
DOI: 10.1177/17562872261463076 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Therapeutic Advances in Urology, online erschienen am 03.07.2026. Verfasst von I-Hsuan Alan Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Transplant Surgery, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Triplet therapy with androgen deprivation therapy (ADT), docetaxel, and androgen receptor pathway inhibitors (ARPIs), either darolutamide or abiraterone, is one of the standard treatments for metastatic hormone-sensitive prostate cancer (mHSPC); however, no randomized trial has directly compared both ARPIs within this regimen. Given practical and financial constraints, a head-to-head randomized trial directly comparing these ARPIs may be unlikely.
Objective
To compare the real-world effectiveness of darolutamide- versus abiraterone-based triplet therapy in patients with mHSPC.
Design
Retrospective cohort study using a multinational electronic health record network.
Methods
We conducted a retrospective cohort study using the TriNetX research network. Patients with mHSPC treated with darolutamide- or abiraterone-based triplet therapy were identified and balanced using propensity-score matching. The primary outcome was overall survival (OS), and the secondary outcome was time to next treatment (TTNT), defined by treatment switch. Prespecified subgroup analyses focused on age, cardiometabolic comorbidities, and polypharmacy-related medication use.
Results
Among 1607 eligible patients, 1252 were included after propensity score matching (626 per group). Darolutamide-based triplet therapy was associated with longer OS compared with abiraterone (hazard ratio (HR) 0.42). A favorable difference in TTNT was also observed (HR 0.66). These associations were consistent across clinically relevant subgroups, including patients aged ⩾65 years and those with ischemic heart disease or diabetes mellitus. In polypharmacy-enriched subgroups, darolutamide-based therapy was consistently associated with more favorable OS and TTNT.
Conclusion
In this large real-world analysis, darolutamide-based triplet therapy was associated with longer OS and TTNT compared with abiraterone-based triplet therapy in patients with mHSPC, particularly among older individuals and those with comorbidities. These findings are hypothesis-generating, suggesting that ARPI selection within triplet therapy may have clinically relevant implications, supporting the need for prospective studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Transplant Surgery, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
- Institute of Clinical Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan.
- Division of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
- Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
- Department of Emergency Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
ORCID-Profile: I-Hsuan Alan Chen, Chih-Yu Yang
Zitieren
APA
Chen, I. A., Chang, R. I., Yu, C. C., Lin, T. P., & Yang, C. Y. (2026). Real-world comparative outcomes of darolutamide- versus abiraterone-based triplet therapy for metastatic hormone-sensitive prostate cancer: a retrospective cohort study. Therapeutic Advances in Urology, 18. https://doi.org/10.1177/17562872261463076
Vancouver
Chen IA, Chang RI, Yu CC, Lin TP, Yang CY. Real-world comparative outcomes of darolutamide- versus abiraterone-based triplet therapy for metastatic hormone-sensitive prostate cancer: a retrospective cohort study. Therapeutic Advances in Urology. 2026;18. doi:10.1177/17562872261463076
BibTeX
@article{Chen2026,
author = {Chen, I-Hsuan Alan and Chang, Ren-In and Yu, Chia-Cheng and Lin, Tzu-Ping and Yang, Chih-Yu},
title = {Real-world comparative outcomes of darolutamide- versus abiraterone-based triplet therapy for metastatic hormone-sensitive prostate cancer: a retrospective cohort study},
journal = {Therapeutic Advances in Urology},
year = {2026},
volume = {18},
doi = {10.1177/17562872261463076}
}
EUVIMED